drugset / Trial / NCT04315298

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

NCT04315298

Phase 2/3 Completed 1912 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata. Phase 3 Cohort 1: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline. Phase 3 Cohort 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.

Timeline

Start
2020-03-18
Primary completion
2020-07-24
Completion
2020-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarilumab Monoclonal antibody 200 mg Intravenous
Subject Sarilumab Monoclonal antibody 400 mg Intravenous
Subject Sarilumab Monoclonal antibody 800 mg Intravenous

Indications